|
業務類別
|
Biotechnology |
|
業務概覽
|
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response andcell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies. |
| 公司地址
| 480 Arsenal Way, Suite 100, Watertown, MA, USA, 02472 |
| 電話號碼
| +1 617 207-8979 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.acrivon.com |
| 員工數量
| 76 |
| Dr. Eric Devroe, PhD |
Chief Operating Officer |
美元 528.75K |
30/04/2026 |
| Ms. Katharine Peterson |
Chief Accounting Officer |
-- |
19/03/2026 |
| Dr. Erick Gamelin, M.D.,PhD |
Chief Development Officer |
-- |
30/04/2026 |
| Ms. Mary-Alice Miller, J.D. |
Chief Legal Officer |
-- |
30/04/2026 |
| Dr. Adam Levy, PhD |
Chief Financial Officer |
-- |
30/04/2026 |
| Dr. Kristina Masson, M.B.A.,PhD |
Director; Executive Vice President, Business Operations and President, Chief Executive Officer, Site Head of Acrivon AB |
美元 594.47K |
30/04/2026 |
| Mr. Peter Blume-Jensen, M.D.,PhD |
Chairman of the Board, President and Chief Executive Officer |
美元 709.89K |
30/04/2026 |
| Dr. Mansoor Raza Mirza, M.D. |
Chief Medical Officer |
-- |
30/04/2026 |
|
|
| Dr. Charles M. Baum, M.D.,PhD |
Independent Director |
30/04/2026 |
| Mr. Michael J. Tomsicek, M.B.A. |
Independent Director |
30/04/2026 |
| Dr. Sharon Shacham, M.B.A.,PhD |
Independent Director |
30/04/2026 |
| Dr. Santhosh Palani, C.F.A.,PhD |
Independent Director |
30/04/2026 |
| Dr. Kristina Masson, M.B.A.,PhD |
Director; Executive Vice President, Business Operations and President, Chief Executive Officer, Site Head of Acrivon AB |
30/04/2026 |
| Dr. Derek DiRocco, PhD |
Independent Director |
30/04/2026 |
| Mr. Peter Blume-Jensen, M.D.,PhD |
Chairman of the Board, President and Chief Executive Officer |
30/04/2026 |
| Dr. Ivana Magovcevic-Liebisch, J.D.,PhD |
Independent Director |
30/04/2026 |
|
|
|
|
